Bedrijfsoverzicht
Bio Green Med Solution, Inc. is a biotechnology entity that operates by distributing, trading, and installing protective and fire safety materials, equipment, and prevention systems, while simultaneously engaging in the research and development of pharmaceuticals. The company operates within the healthcare sector, specifically the biotechnology industry, which implies a focus on innovative medical solutions and safety infrastructure rather than traditional consumer goods. Despite its diverse operational scope, the company's financial scale is defined by a market cap listed as N/A and an annual revenue of $747,000 over the trailing twelve months. The absence of specific market cap data combined with the relatively low revenue figure indicates that the company holds a very small position in the broader healthcare market. Furthermore, the employee count is listed as N/A, suggesting that the organization operates on a minimal scale or that specific headcount metrics are not publicly disclosed, which is common for smaller, specialized firms. This limited operational footprint contrasts with the high-risk nature of the biotechnology industry, where significant capital is often required to move beyond early-stage distribution and R&D phases. The company's historical name, formerly Cyclacel Pharmaceuticals, Inc., adds historical context but does not alter the current financial reality of its current revenue generation capabilities.
Financiële gezondheid
The company reported a revenue of $747,000 for the trailing twelve months, yet this figure masks a severe deficit with a net income of $-14,092,000 and an EBITDA of $-8,422,000. The substantial gap between the minimal revenue and the massive net loss reveals a highly inefficient cost structure where expenses far exceed income, a typical characteristic of deep-stage biotechnology firms or struggling distributors. The free cash flow stands at $-10,077,875, indicating that the company is burning through its liquidity rapidly and lacks the financial flexibility to fund operations without external capital injection. All three margin metrics reflect this distress: the gross margin is -90.1%, the operating margin is -162.5%, and the profit margin is 0.0%. These negative and disproportionate margins indicate that the cost of goods sold and operating expenses are not only consuming all revenue but are also generating losses that exceed total sales, a critical red flag for solvency. On the balance sheet, the company holds $3.50M in cash against only $2,000 in debt, which might appear conservative at first glance, but the debt-to-equity ratio of 0.03 suggests a lack of leverage rather than financial strength. The current ratio of 4.70 technically indicates strong short-term liquidity relative to liabilities, yet this metric is misleading given the negative earnings and cash flow that deplete this cash reserve monthly. Finally, the return on equity is -128.4% and the return on assets is -85.8%, metrics that reveal management is currently destroying value for shareholders and failing to generate returns on the company's asset base.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E are both listed as N/A because the company is not currently profitable, rendering traditional price-to-earnings valuation methods inapplicable. The price-to-book ratio is 0.67, which indicates that the stock is trading at a discount relative to its book value, suggesting the market values the company at less than the net assets it holds on paper. The price-to-sales ratio is N/A and the EV/EBITDA is -0.22; these alternative metrics further highlight the difficulty in valuing a loss-making company with negative earnings power. The stock has a 52-week high of $14.00 and a 52-week low of $0.30, and without a specific current price to calculate the exact percentage, the volatility is evident from this extreme range. The beta value of -0.53 is highly unusual for an equity security and suggests an inverse correlation to the broader market, implying that the stock tends to move in the opposite direction of the market index during periods of volatility. This negative beta indicates a unique risk profile that does not align with standard market benchmarks, making the valuation even more challenging to interpret using conventional financial models.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue due to the absence of historical growth data. The company lists a dividend yield of 61.6%, which is exceptionally high, while the payout ratio is N/A; such a yield combined with massive net losses and negative free cash flow suggests the dividend is not sustainable given the company's inability to generate positive earnings. Since the payout ratio cannot be calculated with positive earnings, the company effectively cannot sustain this dividend level without depleting its remaining cash reserves or cutting the dividend entirely. The overall growth and income profile is characterized by a lack of measurable growth metrics and a potentially unsustainable dividend policy that conflicts with the company's severe financial losses.